Serum level of fetuin B is associated with osteoporosis: a 4-year prospective study in China Abstract Purpose: As a novel hepatokine, fetuin B involves in various functions of energy metabolism. Recent advance reveals a complex interaction between bone and liver via the secretion of hepatokines. The association between serum fetuin B and osteoporosis was evaluated in a 4-year hospital-based prospective study of 1,370 Chinese postmenopausal women.
Recent evidence suggests that the endocrine system plays an essential role in bone metabolism [1] . Proteins produced by adipocytes and liver may be involved in the pathophysiology of osteoporosis [2] and altered levels of adipokines and hepatokines have been reported in patients with osteoporosis [2] [3] [4] [5] .
Recent studies have suggested that fetuin, an endogenous inhibitor of the insulin receptor tyrosine kinase [6, 7] , is involved in osteogenesis, mineralization and inflammation [8, 9] . The latest studies found elevated fetuin B levels in obese mice [10] and humans with steatosis [11, 12] , which suggests a link between fetuin B and energy metabolism [11] . In one study, in vitro data indicated that fetuin B may lead to insulin resistance in myotubes and hepatocytes and rodent data indicated that the administration of fetuin B caused glucose intolerance rather than insulin resistance [11] . These data support a role for fetuin B in the metabolism of glucose and lipid [13, 14] . In addition, Jung et al. [15] reported that fetuin B was associated with the development of acute myocardial infarction.
More studies on cytokines have focused on the connections between these proteins and bone physiological function. Recent evidence links obesity, metabolic syndrome and diabetes to osteoporosis [16, 17] . This evidence reveals complex communication between the bone and the liver, which mutually regulate physical functions via the secretion of hepatokines, as indispensable modulators of bone remodelling [12, 18] . As a liver-derived molecule, fetuin B may be involved in the endocrine-bone axis. In this 4-year hospital-based cohort study of 1,370 Chinese postmenopausal women, the association between serum fetuin B and osteoporosis was evaluated.
Methods

Study design and patients
The hospital-based cohort study recruited the postmenopausal women who took the annual health examination at the Jintan Affiliated Hospital of Jiangsu University from January to December 2012. In 2016, the participants were invited back for re-assessment. Of the 1,370 subjects who participated in the initial study, 650 were eventually enrolled in the follow-up study. Subjects with the following medical conditions were excluded from the study: malignant tumor; severe cardiopulmonary disease; stroke; virus hepatitis; liver cirrhosis; jaundice; renal insufficiency; endocrine diseases; inflammatory rheumatism; and the use of estrogens or steroids. The research was approved by the Ethics Committee of the Jintan Affiliated Hospital, Jiangsu University, in accordance with the Helsinki Declaration of 1964. Before participation, each participant gave written informed consent.
Examinations
All participants received BMD scans of their femoral neck and lumbar spines (L2-L4) using dual energy X-ray absorptiometry (Lunar Prodigy, General Electric Medical Systems, USA). A T score of less than -2.5 was diagnosed as osteoporosis. Blood samples were obtained and frozen for the further evaluation of serum fetuin B levels by using enzyme-linked immunosorbent assay (ELISA) (catalogue no. SEB860Hu; USCN Life Science, China). The intra-and inter-assay variations of serum fetuin B measurement were 6.7% and 11.5%, respectively. Routine blood chemistry analyses and anthropometric exams were performed in our hospital, as reported previously [19] . Menopause was defined as the absence of menstruation for ≥ 1 year and was confirmed by a serum follicle-stimulating hormone assay.
Statistical methods
The Student's unpaired t test and χ2 test were used to compare the parameters between two groups. The χ2 test was used for testing the difference of osteoporosis within the quartiles of serum Fetuin B. Pair-sample t test was used for comparison between baseline and follow-up. To assess the association between serum fetuin B at baseline and incidence of osteoporosis, the adjusted odds ratio (OR) and 95% confidence interval (CI) were calculated, with a multivariable logistic regression model. Pearson/Spearman bivariate correlation analyses were performed between fetuin B and the anthropometric/biomedical parameters. All statistical analyses were performed by SPSS (version 21.0, SPSS, USA). Power of sample size was calculated using G*Power (version 3.1, Heinrich-Heine-Universität, Germany) [20] . A two-sided P < 0.05 was considered statistically significant.
Results
Of the 1,370 participants in the original baseline study (2012), 650 subjects were included in the 4-year follow-up (2016) (Figure 1 ). The osteoporosis incidence rate at this 4-year follow-up was 17.8% (116/650). The annual incidence rate was 4.5%. Table 1 indicates the baseline characteristics of the participants in 2012. Serum fetuin B level was significantly higher in patients with osteoporosis (106.7 ± 17.6 μg/ml) than it in controls (86.3 ± 17.5 μg/ml) (P < 0.001, Figure 2A ). In all the postmenopausal women, serum fetuin B level was positively correlated with triglycerides (TG) (r = 0.227, P = 0.001) but negatively correlated with femoral BMD (r = -0.426, P < 0.001) and lumbar BMD (r = -0.332, P < 0.001) ( Table 2) .
At the 4-year follow-up, 650 postmenopausal women who were without osteoporosis at the baseline study completed the re-evaluation: a total of 116 of the subjects had developed osteoporosis, while 534 subjects had not.
As shown in Figure 2B , the fetuin B concentration was significantly higher in subjects who developed osteoporosis (n = 116, 114.9 ± 22.7 μg/ml) compared with subjects who did not develop (n = 534, 81.4 ± 22.5 μg/ml) (P < 0.001).
Comparison between baseline and 4-year follow-up fetuin B levels revealed a difference in subjects who developed osteoporosis (P < 0.001, Figure 2C ).
In Figure 3 , when stratified by quartile of baseline serum fetuin B levels, subjects in the Q1 of fetuin B had an incidence rate of 9.9% at the 4-year follow-up. The incidence rates of osteoporosis increased to 30.2% by Q4 (P for trend < 0.001). Furthermore, a higher serum level of fetuin B in the baseline study was associated with the incidence of osteoporosis at the 4-year follow-up (adjusted OR = 1.179, 95% CI [1.119 -1.243], P = 0.009), after adjustment, as shown in Table 3 .
Discussion
The connection between the endocrine system and osteoporosis has led to speculation that specific liver-derived proteins are involved in the regulation of bone metabolism [21] . A recent study has suggested that hepatokines may play a role in liver-bone axis mediation [22] . As a liver-derived protein, fetuin B might also play a role in the endocrine-bone axis.
This study is the first to report the role of serum fetuin B in the development of osteoporosis. In the 2012 hospital-based LDL-C 0.008 0.910 * Spearman correlation analysis; BMI, body mass index; FPG, fasting plasma glucose; FBMD: femoral bone mineral density; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment insulin resistance; LBMD: lumbar bone mineral density; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.
* Spearman correlation analysis; BMI, body mass index; FPG, fasting plasma glucose; FBMD: femoral bone mineral density; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment insulin resistance; LBMD: lumbar bone mineral density; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides.
* Spearman correlation analysis; BMI, body mass index; FPG, fasting plasma glucose; FBMD: femoral bone mineral density; HDL-C, high-density lipoprotein cholesterol; HOMA-IR, homeostasis model assessment insulin resistance; LBMD: lumbar bone mineral density; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides. cohort study, we previously reported that serum levels of fetuin B were higher in postmenopausal women with osteoporosis. Serum fetuin B level was positively correlated with TG, providing evidence for the relationship between fetuin B and obesity and dyslipidemia, as was reported previously [12] . On the other hand, both femoral and lumbar BMDs correlated negatively with the serum fetuin B levels. At the 4-year follow-up, serum fetuin B levels increased further with the development of osteoporosis. Thus, our findings indicate a role of fetuin B in the energy metabolism and pathophysiology of osteoporosis, which might relate with the complex liver-bone axis.
Some limitations merit comment. Firstly, this hospital-based longitudinal study enrolled subjects at one urban medical center. Thus, there might be potential selection bias, and the findings should be interpreted with caution. Furthermore, the 4-year follow-up had a high dropout rate (41.3%, 457/1,107). Half of the follow-up subjects (43.3%, 198/457) were lost due to medical reasons, including malignant tumor, cardiopulmonary disease and stroke, which may reflect the population enrolled (older urban postmenopausal women). Lastly, the levels of vitamin D and other cytokines were not measured.
This hospital-based prospective cohort study, conducted in the postmenopausal women, revealed that serum fetuin B levels increased as the development of osteoporosis. More population-based studies in the future are needed to explore the underlying mechanism of fetuin B in the pathophysiology of osteoporosis. . Incidence rate of osteoporosis in the 4-year follow-up by quartile of fetuin B levels at baseline (P for trend < 0.001).
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